Curcumin

Curcumin, the yellow polyphenol in turmeric, has genuinely useful but modest evidence for joint pain, post-exercise recovery, and metabolic markers — and a newly recognised, occasionally serious liver-injury signal that tracks the very "high-absorption" products marketed for longevity.

Turmeric (Curcuma longa) has been a kitchen and traditional-medicine staple for centuries, and curcumin — the diferuloylmethane pigment that makes up roughly 3% of the dried root by weight — is the molecule behind most of its claimed effects. In cells and animals it touches almost every fashionable longevity pathway at once: it activates AMP-activated protein kinase (AMPK, the energy sensor switched on by exercise and fasting), inhibits mTOR (the growth pathway), raises sirtuin and autophagy activity, and damps the NF-κB inflammatory cascade. That mechanistic breadth is exactly why curcumin is oversold. The human trials are narrower, the effect sizes are modest, and the past few years have added a real safety caveat that didn't exist when turmeric was just a spice.

What the evidence actually supports

Joint pain and osteoarthritis — Moderate. This is curcumin's best-supported use. A meta-analysis of randomised arthritis trials found that curcumin extract (around 1,000 mg/day) reduced pain and stiffness about as much as non-steroidal anti-inflammatory drugs such as ibuprofen and diclofenac, with fewer gastrointestinal side effects.^[1] The trials are mostly short (8–12 weeks), small, and often industry-funded, so "comparable to an NSAID for mild-to-moderate knee osteoarthritis" is the honest ceiling.

Exercise recovery — Moderate. Curcumin does not make you fitter — it does not raise VO₂ max, aerobic capacity, or strength during a session. What it does, fairly reliably, is blunt the soreness and muscle-damage markers after hard or unaccustomed exercise. A meta-analysis of randomised trials found that supplementation lowered creatine kinase, lactate dehydrogenase, and the lipid-peroxidation marker malondialdehyde at 24–72 hours post-exercise, and reduced subjective delayed-onset muscle soreness.^[2] Useful for training through a heavy block; not an ergogenic aid.

Metabolic markers — Moderate, mostly in people who are already impaired. Pooled randomised data show real but small improvements concentrated in adults with prediabetes, type 2 diabetes, or metabolic syndrome — not in already-healthy people. A dose-response meta-analysis of 34 trials reported reductions in fasting glucose of roughly 0.6 mmol/L (about 10 mg/dL), HbA1c of about 0.3 percentage points, and improved insulin sensitivity.^[3] Systolic blood pressure falls a little (about 3 mmHg, more in people near hypertension),^[4] and a small mechanistic trial found that 2,000 mg/day for 12 weeks improved blood-vessel function in healthy middle-aged and older adults by raising nitric-oxide availability.^[5]

Cognition — Weak to preliminary. The headline trial is small: an 18-month, placebo-controlled study at UCLA gave non-demented adults aged 50–90 a nanoparticle curcumin (90 mg twice daily) and reported better working memory and mood, alongside reduced amyloid and tau signal on brain imaging.^[6] It is one positive trial in roughly 40 participants on the active arm — hypothesis-generating, not established.

Bone, cancer, "epigenetic age reversal" — Weak / preliminary. Bone-density benefits are essentially all rodent data. The oncology literature is preclinical or adjuvant. And the widely-shared claim that curcumin "reverses the epigenetic clock by 3 years" comes from a small pilot trial of a whole diet — curcumin plus green tea, rosemary, garlic, berries, sleep and exercise advice — not curcumin in isolation, so it says nothing about the supplement on its own.^[7] A 2024 umbrella review of pooled curcumin meta-analyses reached the sober bottom line: across dozens of outcomes, most of the statistically significant effects rest on low- or very-low-quality evidence.^[8]

The bioavailability problem — and why the label matters

Plain curcumin is almost useless taken by mouth. It barely dissolves in water, degrades in the gut, and what little is absorbed is rapidly conjugated by the liver into metabolites with roughly ten-fold lower antioxidant activity that cannot cross into the brain.^[9] The typical Indian diet — about 2.5 g of turmeric a day — delivers only 60–100 mg of curcumin, with negligible systemic absorption. This is why every clinical formulation is engineered to get around first-pass metabolism:

Approach	Example	What it does
Piperine (black-pepper alkaloid)	Curcumin + piperine	Blocks the liver's conjugating enzymes, raising blood levels up to ~20-fold — but mostly the conjugated (less active) metabolites, and it is also the formulation most prone to drug interactions
Phytosome (lipid complex)	Meriva	Bound to phosphatidylcholine for better solubility; the form behind much of the joint and recovery data
Nanoparticle / colloidal	Theracurmin	Sub-micron particles raise free-curcumin levels; the form used in the cognition trial at low absolute doses
Essential-oil complex	BCM-95	Reconstituted with turmerones; ~7-fold higher absorption than raw powder

The practical consequence: dose recommendations are meaningless without naming the formulation, and raw turmeric powder or culinary curry does not reach the blood levels used in trials.

The catch: liver injury from high-absorption products — Caution

Here is the paradox. Ordinary turmeric, and even unformulated curcumin at very high doses (8–12 g/day in dose-escalation studies), is well tolerated and may even lower liver enzymes.^[10] But the same engineering that finally made curcumin absorbable also made it capable of harming the liver. The US National Institutes of Health LiverTox database now classifies turmeric/curcumin as a well-documented cause of clinically apparent liver injury, and the cases cluster around the high-bioavailability products — especially those using piperine or lipid-nanoparticle delivery.^[11]

Key features of the signal:

It is idiosyncratic, not dose-toxic. The injury is an immune-mediated reaction, not simple overdose, which is why it is unpredictable.
There is a strong genetic risk marker. The HLA-B*35:01 immune-gene variant is carried by 10–15% of the general population but is found in the majority of curcumin liver-injury cases.^[12]
Onset is delayed. Symptoms — fatigue, nausea, poor appetite, then dark urine and jaundice — typically appear after 1–4 months of continuous use, with liver-enzyme (ALT) spikes that can exceed 1,000 U/L and mimic autoimmune hepatitis.
It usually resolves on stopping, within 1–3 months, but acute liver failure and rare fatalities have occurred when people kept taking the product after symptoms began.^[13]

This is not a reason for most people to fear a turmeric latte. It is a reason to treat high-dose, "enhanced-absorption" curcumin capsules as a pharmacologically active drug rather than a benign botanical.

Drug interactions — Caution

Bioavailable curcumin modulates two of the body's main drug-handling systems — the cytochrome P450 3A4 enzyme (which metabolises roughly half of all prescription drugs) and the P-glycoprotein efflux pump — and it does so unpredictably, suppressing them in the gut while inducing them in the liver.^[14] Combined with curcumin's own mild blood-thinning and glucose-lowering effects, this creates several interactions worth taking seriously:

Anticoagulants and antiplatelets (warfarin, clopidogrel, aspirin, NSAIDs) — additive bleeding risk.
Glucose-lowering drugs (metformin, insulin, SGLT2 inhibitors) — additive risk of low blood sugar.
Statins — altered statin levels can raise the risk of statin-associated muscle symptoms, though curcumin has also been studied as an adjunct for them.^[15]
Chemotherapy and immunosuppressants — unpredictable changes in drug exposure; not to be combined without oncology oversight.

If you take any of these, do not start high-dose curcumin without checking with the prescriber.

Practical guidance

Pick a use case before a product. The defensible reasons to take it are mild-to-moderate osteoarthritis pain and recovery from heavy training. For general "anti-aging," the human evidence does not justify it.
Match dose to formulation (these are the doses studied, not raw-powder equivalents): phytosome (e.g. Meriva) ~1,000 mg/day split in two for joints and recovery; nanoparticle (e.g. Theracurmin) ~90–180 mg/day; piperine-boosted standard curcumin 1,000–1,500 mg/day with 10–20 mg piperine — effective but the highest interaction risk.
Take it with a fatty meal. Curcumin is fat-soluble, and absorption is much higher with dietary fat.
Don't take it continuously for years without thought. Given the delayed liver-injury signal, a sensible pattern is time-limited courses (e.g. 8–12 weeks for a flare or training block) rather than indefinite daily use, and stopping at the first sign of unexplained fatigue, nausea, or dark urine.
Monitor if you use it long-term, particularly the high-absorption forms — include liver enzymes (ALT, AST, ALP, GGT) in routine bloodwork. See Midlife labs.
Skip it if you are on anticoagulants or are about to have surgery, on diabetes medication without supervision, pregnant (high doses), or have known liver disease.

What's overrated

The framing of curcumin as a caloric-restriction-mimicking "geroprotector" that slows biological aging is mechanism dressed up as outcome. The AMPK, mTOR, sirtuin and senolytic effects are almost all from cells, yeast, flies, and rodents; the human trials that exist are short, surrogate-endpoint, and weighted toward impaired populations. There is no human trial showing curcumin extends life or slows aging — and the same is true of the broader "longevity stack" it is often sold alongside (NMN, resveratrol, and the rest). The realistic verdict: a reasonable anti-inflammatory option for joints and recovery, in a well-formulated product, used with awareness of the liver and drug-interaction risks — not a longevity drug.